Hansoh Pharmaceutical Group
Innovation-led pharmaceutical company with marketed medicines and a broad clinical pipeline spanning oncology and other major disease areas.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · Non-small Cell Lung Cancer
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung CancerPhase 3 · Recruiting · Small Cell Lung Cancer
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerPhase 3 · Recruiting · Ovarian Cancer
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy SubjectsPhase 1 · Recruiting · IgA Nephropathy
A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.Phase 1 · Recruiting · CML, Chronic Phase
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)Phase 1 · Recruiting · Advanced or Metastatic NSCLC
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/hansoh-pharmaceutical-group/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.